In vivo evaluation of Pam2Cys‐modified cancer‐testis antigens as potential self‐adjuvanting cancer vaccines

Aljohani, S., Edmonds, A. G. ORCID: https://orcid.org/0009-0005-5139-8666, Castelletto, V., Seitsonen, J., Hamley, I. W. ORCID: https://orcid.org/0000-0002-4549-0926, Symonds, P., Brentville, V. A., Durrant, L. G. and Mitchell, N. J. ORCID: https://orcid.org/0000-0002-9041-1852 (2025) In vivo evaluation of Pam2Cys‐modified cancer‐testis antigens as potential self‐adjuvanting cancer vaccines. Journal of Peptide Science, 31 (6). e70022. ISSN 1099-1387 doi: 10.1002/psc.70022

Abstract/Summary

Peptide‐based vaccines, formulated with an appropriate adjuvant, offer a versatile platform for targeted cancer immunotherapy. While adjuvants are usually coadministered for nucleic acid and protein vaccines, synthetic peptide antigens afford a more effective opportunity to covalently and regioselectively graft immunostimulatory motifs directly onto the antigen scaffold to yield self‐adjuvanting vaccines. Herein, we explore the synthesis of two tissue‐restricted cancer‐testis antigens (CTAs); New York oesophageal cell carcinoma 1 (NY‐ESO‐1) and B melanoma antigen 4 (BAGE4), both carrying the toll‐like receptor (TLR) agonist, Pam2Cys. These constructs were evaluated in vivo along with a lipid nanoparticle (LNP) preparation of the underexplored BAGE4 melanoma antigen.

Item Type	Article
URI	https://centaur.reading.ac.uk/id/eprint/122949
Identification Number/DOI	10.1002/psc.70022
Refereed	Yes
Divisions	Life Sciences > School of Chemistry, Food and Pharmacy > Department of Chemistry
Publisher	Wiley
Download/View statistics	View download statistics for this item